CoChat

The DOI matches its Crossref record; 273 of the 273 references it cites were found in a registry or an index; none of the 234 sources its claims cite is checked for support yet.

Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations

Open access
Wang, Jingqi, Fourriere, Lou, Gleeson, Paul A. · 2024 · Biochemical Journal

Abstract

The production of neurotoxic amyloid-β peptides (Aβ) is central to the initiation and progression of Alzheimer's disease (AD) and involves sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. APP and the secretases are transmembrane proteins and their co-localisation in the same membrane-bound sub-compartment is necessary for APP cleavage. The intracellular trafficking of APP and the β-secretase, BACE1, is critical in regulating APP processing and Aβ production and has been studied in several cellular systems. Here, we summarise the intracellular distribution and transport of APP and its secretases, and the intracellular location for APP cleavage in non-polarised cells and neuronal models. In addition, we review recent advances on the potential impact of familial AD mutations on APP trafficking and processing. This is critical information in understanding the molecular mechanisms of AD progression and in supporting the development of novel strategies for clinical treatment.

Overview

CoChat Summary

TL;DR

This review summarizes the cell biology of APP trafficking and processing, emphasizing that APP and BACE1 are largely segregated and that amyloidogenic cleavage can occur in multiple compartments, especially the Golgi/TGN and endosomes. It highlights that familial AD mutations, notably APP Swedish, can shift the major processing site to the secretory pathway/Golgi and are linked to organelle abnormalities.

Key findings

  • APP and BACE1 follow distinct post-Golgi itineraries in non-polarised cells: APP is transported from the TGN to early endosomes via AP4/Arl5b with low plasma membrane levels, while BACE1 goes directly to the plasma membrane and recycles; the TGN/Golgi and early endosomes are prime convergence sites.
  • In primary neurons, APP and BACE1 show only low co-localisation under physiological conditions; synaptic activity can increase their convergence and β-cleavage products (C99) and Aβ secretion.
  • The familial APP Swedish mutation (K595/M596→N595/L596 in APP695) is adjacent to the β-cleavage site; purified BACE1 cleaves APPswe faster than APPwt, with synthetic peptide cleavage 10-fold higher and kcat/Km 60-fold higher; APPswe is predominantly cleaved in the secretory pathway/Golgi, whereas APPwt is preferentially cleaved in the endocytic pathway.
  • Familial AD mutations are numerous (114 APP mutations; >360 PSEN1 and >90 PSEN2 pathogenic mutations), many near the transmembrane domain/cleavage sites; PSEN mutations can alter APP trafficking and cause organelle abnormalities, including Golgi fragmentation and enlarged endosomes in iPSC-derived neurons.

Methods

  • Narrative review synthesizing published literature on intracellular distribution/trafficking of APP and secretases, sites of APP processing in non-polarised cells and neuronal models, and effects of familial AD mutations.
  • Evidence base includes immortalised cell lines, primary rodent neurons, rodent brain sections, human iPSC-derived neurons, and patient/post-mortem tissues; Tables 1–3 summarize localisation, cleavage products, and unanswered questions.
  • Main analysis is qualitative synthesis with figures/tables; no new experimental data, systematic search, or meta-analysis.

Limitations

  • Stated in paper: challenges include comparing different cell lines, overexpression effects, sorting motif/adaptor pleiotropy, antibody specificity, older microscopy resolution limits, steady-state Aβ localisation, multiple mutants in the same line, and multiple processing compartments.
  • Stated in paper: many unanswered questions remain (Table 3), including when/where APP and BACE1 converge in neurons, whether disease mutations alter processing location in primary neurons, and the role of cholesterol-rich microdomains.
  • Evident from text: as a narrative review, it does not systematically appraise study quality or quantify effects; conclusions rely on cited studies, many from non-neuronal or overexpression systems, with limited human neuronal data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1042/bcj20240056

Cites

273 of 273 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. APP processing. Full-length APP can be cleaved sequentially by different secretases to give rise to different products. (A) In the non-amyloidogenic pathway, APP is cleaved by α-secretase, producing sAPPα and C83 (CTFα) fragments. C83 (CTFα) can be further cleaved by γ-secretase, generating p3 and AICD fragments. p3 is not neurotoxic. (B) In the amyloidogenic pathway, APP is cleaved by β-secretase, producing sAPPβ and C99 (CTFβ). Subsequent cleavage of C99 (CTFβ) by γ-secretase leads to the formation of AICD and Aβ. Soluble Aβ can be secreted and aggregate into amyloid plaques, a hallmark of Alzheimer's disease. (C) The protein sequence of APP695 close to the secretase cleavage sites. Sequence of the transmembrane domain (TMD, in bold), and flanking sequences of the cytoplasmic tail and the luminal domain of APP are shown. The cleavage sites of α-, β- and γ-secretases are illustrated in blue, red and black, respectively.
Figure 1. APP processing. Full-length APP can be cleaved sequentially by different secretases to give rise to different products. (A) In the non-amyloidogenic pathway, APP is cleaved by α-secretase, producing sAPPα and C83 (CTFα) fragments. C83 (CTFα) can be further cleaved by γ-secretase, generating p3 and AICD fragments. p3 is not neurotoxic. (B) In the amyloidogenic pathway, APP is cleaved by β-secretase, producing sAPPβ and C99 (CTFβ). Subsequent cleavage of C99 (CTFβ) by γ-secretase leads to the formation of AICD and Aβ. Soluble Aβ can be secreted and aggregate into amyloid plaques, a hallmark of Alzheimer's disease. (C) The protein sequence of APP695 close to the secretase cleavage sites. Sequence of the transmembrane domain (TMD, in bold), and flanking sequences of the cytoplasmic tail and the luminal domain of APP are shown. The cleavage sites of α-, β- and γ-secretases are illustrated in blue, red and black, respectively.CC BY · PubMed Central
Figure 2. Trafficking itineraries of APP and the β-secretase BACE1 in non-polarised cells. Intracellular trafficking itineraries of APP and the β-secretase BACE1 in non-polarised cells are illustrated in blue and red, respectively. Both APP and BACE1 are synthesised in the endoplasmic reticulum (ER) and transported to the Golgi apparatus. APP and BACE1 segregate within the Golgi stack and are sorted into different transport carriers at the trans-Golgi network (TGN). The bulk of APP is transported to the early endosomes and then transported along the late endosome-lysosome pathway in cultured cells using protocols to synchronise trafficking of APP from the ER [47,48]. Low levels of APP are transported to the cell surface as quantified by TIRF [48] and are present at steady state as assessed by subcellular fractionation [49]. In contrast, BACE1 is sorted directly to the plasma membrane [50]. BACE1 can be actively internalised and recycled through the recycling endosomes, while APP showed minimal localisation to the recycling endosomes. Hence, the TGN and the early endosomes serve as potential sites for the β-cleavage of APP.
Figure 2. Trafficking itineraries of APP and the β-secretase BACE1 in non-polarised cells. Intracellular trafficking itineraries of APP and the β-secretase BACE1 in non-polarised cells are illustrated in blue and red, respectively. Both APP and BACE1 are synthesised in the endoplasmic reticulum (ER) and transported to the Golgi apparatus. APP and BACE1 segregate within the Golgi stack and are sorted into different transport carriers at the trans-Golgi network (TGN). The bulk of APP is transported to the early endosomes and then transported along the late endosome-lysosome pathway in cultured cells using protocols to synchronise trafficking of APP from the ER [47,48]. Low levels of APP are transported to the cell surface as quantified by TIRF [48] and are present at steady state as assessed by subcellular fractionation [49]. In contrast, BACE1 is sorted directly to the plasma membrane [50]. BACE1 can be actively internalised and recycled through the recycling endosomes, while APP showed minimal localisation to the recycling endosomes. Hence, the TGN and the early endosomes serve as potential sites for the β-cleavage of APP.CC BY · PubMed Central
Figure 3. APP trafficking and sites of processing in primary rodent neurons. APP trafficking in primary rodent neuronal models is complex, as neurons are comprised of polarised subdomains (axon and dendrites) in addition to the cell body (soma). APP is distributed in primary rodent neurons in the soma, dendrite, and axon, as well as both pre- and post-synapses. In the soma, APP is mainly associated with the Golgi and Golgi-derived vesicles, and the early and recycling endosomes. Newly synthesised APP can be transported to the axon and dendrites. APP can also be transcytosed from the axonal domain to the dendrites. Limited levels of APP and BACE1 co-localisation have been observed in the Golgi and Golgi-derived vesicles, as well as recycling endosomes.
Figure 3. APP trafficking and sites of processing in primary rodent neurons. APP trafficking in primary rodent neuronal models is complex, as neurons are comprised of polarised subdomains (axon and dendrites) in addition to the cell body (soma). APP is distributed in primary rodent neurons in the soma, dendrite, and axon, as well as both pre- and post-synapses. In the soma, APP is mainly associated with the Golgi and Golgi-derived vesicles, and the early and recycling endosomes. Newly synthesised APP can be transported to the axon and dendrites. APP can also be transcytosed from the axonal domain to the dendrites. Limited levels of APP and BACE1 co-localisation have been observed in the Golgi and Golgi-derived vesicles, as well as recycling endosomes.CC BY · PubMed Central
Figure 4. Mapping of mutations in APP. The protein sequence of the transmembrane domain (TMD, bold), and the flanking sequences of the cytoplasmic tail the luminal domain of APP695 are shown. The secretases cleavage sites are illustrated as in Figure 1. The Swedish mutation, a double mutation substituting K595 and M596 to N595 and L596, is mapped adjacent to the β-cleavage site. The protective Icelandic mutation, A598T, is illustrated in green. Other pathogenic APP mutations identified in familial Alzheimer's disease are labelled in red. Details of the pathogenic mutations which map in the transmembrane domain of APP are identified in the figure table.
Figure 4. Mapping of mutations in APP. The protein sequence of the transmembrane domain (TMD, bold), and the flanking sequences of the cytoplasmic tail the luminal domain of APP695 are shown. The secretases cleavage sites are illustrated as in Figure 1. The Swedish mutation, a double mutation substituting K595 and M596 to N595 and L596, is mapped adjacent to the β-cleavage site. The protective Icelandic mutation, A598T, is illustrated in green. Other pathogenic APP mutations identified in familial Alzheimer's disease are labelled in red. Details of the pathogenic mutations which map in the transmembrane domain of APP are identified in the figure table.CC BY · PubMed Central
Figure 5. Model of the trafficking and processing of APP under healthy and disease conditions. Under physiological conditions, APP and BACE1 are well segregated in neurons. The partitioning of APP and BACE1 regulates APP processing and is associated with only low levels of Aβ production. Under conditions which promote Alzheimer's disease, dysregulation of APP trafficking and/or processing leads to elevated levels of APP and BACE1 convergence, resulting in an increased production of intracellular Aβ probably in the Golgi apparatus (somatic and dendritic), the early endosomes and in the recycling endosomes. The production of intracellular Aβ subsequently results in organelle abnormalities, including but not limited to Golgi disruption, endosome enlargement and lysosomal abnormalities. Perturbation of the architecture and membrane subdomains of the Golgi and endosomes may then lead to dysregulated protein sorting and trafficking, a reduction in the partitioning of APP and BACE1 in membranes and a further increase APP processing and production of Aβ. The intracellular stress caused by organelle abnormalities and Aβ production could have broader effects on the intracellular organisation and trafficking (i.e.: of synaptic receptors) which then lead to neuronal defects.
Figure 5. Model of the trafficking and processing of APP under healthy and disease conditions. Under physiological conditions, APP and BACE1 are well segregated in neurons. The partitioning of APP and BACE1 regulates APP processing and is associated with only low levels of Aβ production. Under conditions which promote Alzheimer's disease, dysregulation of APP trafficking and/or processing leads to elevated levels of APP and BACE1 convergence, resulting in an increased production of intracellular Aβ probably in the Golgi apparatus (somatic and dendritic), the early endosomes and in the recycling endosomes. The production of intracellular Aβ subsequently results in organelle abnormalities, including but not limited to Golgi disruption, endosome enlargement and lysosomal abnormalities. Perturbation of the architecture and membrane subdomains of the Golgi and endosomes may then lead to dysregulated protein sorting and trafficking, a reduction in the partitioning of APP and BACE1 in membranes and a further increase APP processing and production of Aβ. The intracellular stress caused by organelle abnormalities and Aβ production could have broader effects on the intracellular organisation and trafficking (i.e.: of synaptic receptors) which then lead to neuronal defects.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 158 Not checked · 55 Own results and interpretations

160 more claims

Create a free account to see all 214 claims and to verify the 233 references still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Citations

Cites

Show all 273 references

Research works printed but not linked: 1

  1. 2000, Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis, Ann. Neurol., 47, 249, 10.1002/1531-8249(200002)47:2<249::aid-ana18>3.0.co;2-8 · doi:10.1002/1531-8249(200002)47:2<249::aid-ana18>3.0.co;2-8

Cited by

See all 27

Metadata

Authors
Wang, J., Fourriere, L., & Gleeson, P. A.
Affiliations
  • The University of Melbourne (AU)
  • Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria 3010, Australia
Corresponding author
Gleeson, Paul A.
Venue
Biochemical Journal
Published
2024-09-20
Volume
481
Issue
19
Pages
1297-1325
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W4402681980
Cited by
27
References
273
Citations by year
2026: 19 · 2025: 8
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • Biochemical Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Medical Research Council
  • National Health and Medical Research Council (2013384)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid precursor protein, amyloid-beta, Alzheimer's disease, familial Alzheimer's disease mutations, BACE1, beta-secretase, gamma-secretase, APP processing, intracellular trafficking, APP cleavage, neuron models
MeSH terms
Alzheimer Disease, Animals, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Protein Transport, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations. https://app.cochat.ai/papers/10.1042/bcj20240056
The paper
Wang, J., Fourriere, L., & Gleeson, P. A. (2024). Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations. Biochemical Journal. https://doi.org/10.1042/bcj20240056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.